{"id":"https://openalex.org/W3206344296","doi":null,"title":"An\u00e1lisis exploratorio de seguridad e inmunogenicidad de vacuna HER-1/VSSP en pacientes asintom\u00e1ticos con c\u00e1ncer de pr\u00f3stata metast\u00e1sico","display_name":"An\u00e1lisis exploratorio de seguridad e inmunogenicidad de vacuna HER-1/VSSP en pacientes asintom\u00e1ticos con c\u00e1ncer de pr\u00f3stata metast\u00e1sico","publication_year":2021,"publication_date":"2021-10-05","ids":{"openalex":"https://openalex.org/W3206344296","mag":"3206344296"},"language":"es","primary_location":{"id":"mag:3206344296","doi":null,"is_oa":false,"landing_page_url":"http://revoncologia.sld.cu/index.php/onc/article/view/153/0","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039928116","display_name":"Iraida Caballero Aguirrechu","orcid":"https://orcid.org/0000-0002-1044-6052","observed_orcids":["https://orcid.org/0000-0002-1044-6052"]},"institutions":[{"id":"https://openalex.org/I2799943988","display_name":"Hermanos Ameijeiras Hospital","ror":"https://ror.org/05328fn02","country_code":"CU","type":"healthcare","lineage":["https://openalex.org/I2799943988"]}],"countries":["CU"],"is_corresponding":false,"raw_author_name":"Iraida Caballero Aguirrechu","raw_affiliation_strings":["Hospital Hermanos Ameijeiras"],"raw_orcid":"https://orcid.org/0000-0002-1044-6052","affiliations":[{"raw_affiliation_string":"Hospital Hermanos Ameijeiras","institution_ids":["https://openalex.org/I2799943988"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Belinda S\u00e1nchez P\u00e9rez","orcid":"https://orcid.org/0000-0003-1659-5427","observed_orcids":["https://orcid.org/0000-0003-1659-5427"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Belinda S\u00e1nchez P\u00e9rez","raw_affiliation_strings":["Centro de Inmunologia Molecular"],"raw_orcid":"https://orcid.org/0000-0003-1659-5427","affiliations":[{"raw_affiliation_string":"Centro de Inmunologia Molecular","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110428801","display_name":"Amparo Mac\u00edas Abraham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amparo Mac\u00edas Abraham","raw_affiliation_strings":["CIM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CIM","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051119342","display_name":"Lisset Chao Garc\u00eda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lisset Chao Garc\u00eda","raw_affiliation_strings":["CIM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CIM","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083028754","display_name":"Ivette Orosa-V\u00e1zquez","orcid":"https://orcid.org/0000-0003-3818-3271","observed_orcids":["https://orcid.org/0000-0003-3818-3271"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivette Orosa V\u00e1zquez","raw_affiliation_strings":["CIM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CIM","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111585420","display_name":"Irlis S\u00e1nchez Rojas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799943988","display_name":"Hermanos Ameijeiras Hospital","ror":"https://ror.org/05328fn02","country_code":"CU","type":"healthcare","lineage":["https://openalex.org/I2799943988"]}],"countries":["CU"],"is_corresponding":false,"raw_author_name":"Irlis S\u00e1nchez Rojas","raw_affiliation_strings":["Hospital Hermanos Ameijeiras"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Hermanos Ameijeiras","institution_ids":["https://openalex.org/I2799943988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003159548","display_name":"Daniel Carballo-Torres","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799943988","display_name":"Hermanos Ameijeiras Hospital","ror":"https://ror.org/05328fn02","country_code":"CU","type":"healthcare","lineage":["https://openalex.org/I2799943988"]}],"countries":["CU"],"is_corresponding":false,"raw_author_name":"Daniel Carballo Torres","raw_affiliation_strings":["Hospital Hermanos Ameijeiras"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Hermanos Ameijeiras","institution_ids":["https://openalex.org/I2799943988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069031794","display_name":"Daines Mari\u00f1o de la Puente","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159025","display_name":"REACH ETHIOPIA","ror":"https://ror.org/05cfwmz90","country_code":"ET","type":"healthcare","lineage":["https://openalex.org/I4210159025"]}],"countries":["ET"],"is_corresponding":false,"raw_author_name":"Daines Mari\u00f1o de la Puente","raw_affiliation_strings":["HHA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HHA","institution_ids":["https://openalex.org/I4210159025"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042963282","display_name":"Tania Crombet","orcid":"https://orcid.org/0000-0002-2550-7292","observed_orcids":["https://orcid.org/0000-0002-2550-7292"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tania Crombet","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2550-7292","affiliations":[]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"19","issue":"3","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9096999764442444,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9096999764442444,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.08070000261068344,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.8679999709129333},{"id":"https://openalex.org/keywords/asymptomatic-patients","display_name":"asymptomatic patients","score":0.7419999837875366},{"id":"https://openalex.org/keywords/vaccine-safety","display_name":"vaccine safety","score":0.6570000052452087},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.925000011920929},{"id":"https://openalex.org/keywords/active-immunotherapy","display_name":"active immunotherapy","score":0.7990000247955322},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9440000057220459},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8429999947547913},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6520000100135803},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.5709999799728394},{"id":"https://openalex.org/keywords/hormonal-resistance","display_name":"hormonal resistance","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8959599733352661},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.5615170001983643},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5092695951461792},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47210875153541565},{"id":"https://openalex.org/C2778378633","wikidata":"https://www.wikidata.org/wiki/Q2378309","display_name":"Cancer vaccine","level":4,"score":0.4718717932701111},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.44467923045158386},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43396249413490295},{"id":"https://openalex.org/C2777910003","wikidata":"https://www.wikidata.org/wiki/Q1707292","display_name":"Asymptomatic","level":2,"score":0.4327927529811859},{"id":"https://openalex.org/C32611913","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Titer","level":3,"score":0.4320264160633087},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.41171175241470337},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.3771893382072449},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.35667115449905396},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3353744447231293}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3206344296","doi":null,"is_oa":false,"landing_page_url":"http://revoncologia.sld.cu/index.php/onc/article/view/153/0","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2640274823","https://openalex.org/W2122971334","https://openalex.org/W2152105813","https://openalex.org/W2090890051","https://openalex.org/W2091818731","https://openalex.org/W2605219687","https://openalex.org/W2247530819","https://openalex.org/W2037665874","https://openalex.org/W2108470072","https://openalex.org/W2098574945"],"abstract_inverted_index":{"Introduction:":[0],"In":[4],"the":[5,27,40,47,71,92,115,216,259,264,275,286],"context":[6],"of":[7,46,85,108,114,141,174,215,228,236,258],"hormonal":[8],"resistance":[9],"in":[10,14,26,146,213,232,274],"prostate":[11,124,293],"cancer,":[12],"patients":[13,121,217],"a":[15,172,204],"good":[16],"general":[17],"state":[18],"or":[19,196],"asymptomatic":[20,120],"may":[21],"benefit":[22],"from":[23],"active":[24],"immunotherapy":[25],"time":[28],"to":[29,77,239],"progression.":[30],"Objective:":[35],"Evaluate":[39],"safety,":[41],"immunogenicity":[42,266],"and":[43,82,100,135,178,199,201,208],"clinical":[44,74,276],"effect":[45],"human":[48],"epidermal":[49,295],"growth":[50,296],"factor":[51],"receptor":[52],"1":[53],"(HER-1)":[54],"vaccine":[55,89,260],"preparation.":[56],"Methods:":[61],"A":[65,110,182],"preliminary":[66],"report":[67],"was":[68,112,138,167,211,244,248,261,267,271],"developed":[69],"for":[70,117],"Phase":[72],"I":[73],"trial,":[75],"randomized":[76],"two":[78],"dose":[79,287],"groups:":[80],"400":[81],"800":[83],"\u00b5g":[84],"extracellular":[86],"domain":[87],"subcutaneous":[88],"(ECD-":[90],"HER-1),":[91],"first":[93],"five":[94],"doses":[95],"every":[96,102],"14":[97],"days":[98,104],"(induction)":[99],"then":[101],"28":[103],"until":[105],"one":[106,219],"year":[107],"maintenance.":[109],"comparison":[111],"made":[113],"variables":[116],"ten":[118],"immunized":[119],"with":[122,171],"metastatic":[123],"cancer":[125,298],"(":[126],"p":[127],"<":[129],"0.05).":[130],"Adverse":[131],"events":[132,186],"were":[133,187,194,230,283],"analyzed":[134],"classified.":[136],"Identification":[137],"carried":[139],"out":[140],"anti-HER-1":[142,225],"IgG":[143],"antibody":[144,226],"titers":[145,227],"immune":[147,237],"serums":[148,238],"that":[149],"recognize":[150],"tumor":[151,240],"cell":[152,241],"line":[153,242],"A431,":[154],"determining":[155],"myeloid-derived":[156],"suppressor":[157],"cells.":[158],"Results:":[161],"Mean":[165,246],"age":[166],"74":[168],"years":[169],"(62-79),":[170],"predominance":[173],"white":[175],"skin":[176],"color":[177],"Gleason":[179],"score":[180],"7.":[181],"total":[183],"49":[184],"adverse":[185],"recorded":[188],"(13.6%":[189],"related).":[190],"Of":[191],"these,":[192],"31.8%":[193],"severe":[195,198],"very":[197],"life-threatening,":[200],"none":[202],"showed":[203],"causal":[205],"relationship.":[206],"Clinical":[207],"biochemical":[209,278],"progression":[210],"observed":[212,273],"50%":[214],"after":[218],"year's":[220],"follow-up.":[221],"On":[222],"day":[223],"112":[224],"1/600":[229],"detected":[231],"2/10":[233],"patients.":[234],"Non-recognition":[235],"A431":[243],"considered.":[245],"survival":[247],"not":[249,268,272],"achieved.":[250],"Conclusions:":[253],"Administration":[257],"safe,":[262],"but":[263],"expected":[265],"obtained.":[269],"Benefit":[270],"and/or":[277],"response.":[279],"No":[280],"significant":[281],"differences":[282],"found":[284],"between":[285],"groups.":[288],"Key":[290],"words:":[291],"cancer;":[294],"factor;":[297],"vaccine;":[299],"toxicity.":[300]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2021-10-25T00:00:00"}